Legislation On CROs And IRBs Might Be One Fall-Out From Ketek Probe
Executive Summary
The House Energy and Commerce Committee is considering the need for legislation to set new parameters for organizations involved in drug development. Their concern is prompted by the failure of individuals overseeing safety study 3014 for Sanofi-Aventis' Ketek (telithromycin) to report investigator misconduct to FDA
You may also be interested in...
CROs Look Towards Pre-Emptive Standards As FDA Guidance Looms
Some contract research organizations could install new oversight procedures in a pre-emptive move as FDA contemplates its first guidance to regulate the industry
CROs Look Towards Pre-Emptive Standards As FDA Guidance Looms
Some contract research organizations could install new oversight procedures in a pre-emptive move as FDA contemplates its first guidance to regulate the industry
FDA Oversight Of Clinical Trials Could Be Strengthened After Avandia Report
FDA's oversight of clinical trials didn't reach the headlines during coverage of the Senate Finance Committee's report on Avandia safety, but pressure on the agency from Sens. Max Baucus, D-Mont., and Chuck Grassley, R-Iowa, could have far-reaching consequences for how industry conducts research for products in the future